Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-12-23
DOI
10.3389/fonc.2021.798352
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma
- (2021) John H. Baird et al. Blood Advances
- CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma
- (2021) Kai Rejeski et al. BLOOD
- Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report
- (2021) Rebecca Baur et al. Journal for ImmunoTherapy of Cancer
- Allogenic hematopoietic stem cell transplantation for prolonged bone marrow aplasia after chimeric antigen receptor (CAR) T‐cell therapy for relapsed diffuse large B‐cell lymphoma
- (2020) Ayman Qasrawi et al. AMERICAN JOURNAL OF HEMATOLOGY
- G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma
- (2020) Eugenio Galli et al. BONE MARROW TRANSPLANTATION
- Successful sirolimus therapy of an aplastic anemia patient with chronic kidney disease
- (2020) Haiyue Niu et al. MEDICINE
- Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies
- (2020) Tania Jain et al. Blood Advances
- Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.
- (2020) M.-L. Schubert et al. ANNALS OF ONCOLOGY
- Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
- (2020) Jeremy S Abramson et al. LANCET
- How I treat adverse effects of CAR-T cell therapy
- (2020) Lucrecia Yáñez et al. ESMO Open
- Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
- (2020) Marcela V Maus et al. Journal for ImmunoTherapy of Cancer
- Early and late hematologic toxicity following CD19 CAR-T cells
- (2019) Shalev Fried et al. BONE MARROW TRANSPLANTATION
- Recommendations for the management of hemophagocytic lymphohistiocytosis in adults
- (2019) Paul La Rosée et al. BLOOD
- Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA–CAR-T therapy in patient with relapsed myeloma
- (2019) Quande Lin et al. BONE MARROW TRANSPLANTATION
- Incidence and risk factors associated with a syndrome of persistent cytopenias after CAR-T cell therapy (PCTT)
- (2019) George R. Nahas et al. LEUKEMIA & LYMPHOMA
- Sirolimus as a rescue therapy in children with immune thrombocytopenia refractory to mycophenolate mofetil
- (2018) Maurizio Miano et al. AMERICAN JOURNAL OF HEMATOLOGY
- Successful treatment of refractory/relapsed acquired pure red cell aplasia with sirolimus
- (2018) Zhangbiao Long et al. ANNALS OF HEMATOLOGY
- Sirolimus for the treatment of multi-resistant pure red cell aplasia
- (2018) Huijuan Jiang et al. BRITISH JOURNAL OF HAEMATOLOGY
- Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial
- (2018) Zhi-Wei Lai et al. LANCET
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
- (2018) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
- (2018) Kris M. Mahadeo et al. Nature Reviews Clinical Oncology
- ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells
- (2018) Daniel W Lee et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sirolimus as an Effective Agent in the Treatment of Immune Thrombocytopenia (ITP) and Evans Syndrome (ES)
- (2017) Sylwia Jasinski et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome
- (2016) Christian Klemann et al. HAEMATOLOGICA
- Evolution of disease activity and biomarkers on and off rapamycin in 28 patients with autoimmune lymphoproliferative syndrome
- (2016) Christian Klemann et al. HAEMATOLOGICA
- Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial
- (2015) K. L. Bride et al. BLOOD
- Sirolimus for the treatment of multi-resistant autoimmune haemolytic anaemia in children
- (2014) Maurizio Miano et al. BRITISH JOURNAL OF HAEMATOLOGY
- Sirolimus as Maintenance Treatment in an Infant With Life-threatening Multiresistant Pure Red Cell Anemia/Autoimmune Hemolytic Anemia
- (2013) Maurizio Miano et al. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
- Rapamycin passes the torch: a new generation of mTOR inhibitors
- (2011) Don Benjamin et al. NATURE REVIEWS DRUG DISCOVERY
- Relapse of aplastic anemia responsive to sirolimus combined with cyclosporine
- (2011) Guangsheng He et al. PEDIATRIC BLOOD & CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search